Dr. Henri Nico Doods, the firm’s previous President and Head of R&D, will take over as CEO of Hope Medicine Inc., a clinical-stage revolutionary pharma company. He will develop and implement the firm’s strategic goals, guiding the company toward a science-driven, first-in-class focused worldwide biopharmaceutical R&D group by ensuring the achievement of the next clinical milestones.
The former Boehringer Ingelheim Research Beyond Borders Discovery Research Department’s Senior Vice President and Global Head, Dr. Doods, served as the former HopeMed’s Senior Vice President and Global Head. Having worked in pharmaceutical research and development for more than 30 years, Dr. Doods has authored more than 135 papers and contributed to the invention of more than 15 compounds.
“As CEO of HopeMed, Dr. Doods deserves our sincere congratulation. While I’m excited and pleased to be working with the firm, I’m also grateful. As a result of Henri’s hiring, HopeMed’s leadership has been reinforced, and a new environment will be introduced to the rapidly expanding staff as well.” HopeMed’s co-founder, president, and chief operating officer, Sam Lou, agreed.